Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma

The authors would like to note an error in Figures 1 and 2 of this paper. The graph in Figure 1 incorrectly reflected the overall survival (OS), when it should have displayed the progression-free survival (PFS). The caption and median PFS values were correct.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2019-08, Vol.37 (4), p.797-797
Hauptverfasser:	Weiss, Glen J., Blaydorn, Lisa, Beck, Julia, Bornemann-Kolatzki, Kirsten, Urnovitz, Howard, Schütz, Ekkhard, Khemka, Vivek
Format:	Artikel
Sprache:	eng
Schlagworte:	Correction Medicine Medicine & Public Health Oncology Pharmacology/Toxicology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The authors would like to note an error in Figures 1 and 2 of this paper. The graph in Figure 1 incorrectly reflected the overall survival (OS), when it should have displayed the progression-free survival (PFS). The caption and median PFS values were correct.
ISSN:	0167-6997 1573-0646
DOI:	10.1007/s10637-019-00763-x